Trial Profile
Efficacy and Safety of Cerebrolysin on Neurodevelopmental Outcome of Preterm Infants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Congenital disorders; Neurodegenerative disorders
- Focus Therapeutic Use
- 12 Mar 2021 Status changed from recruiting to completed.
- 27 Apr 2018 New trial record